These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 36559247)

  • 1. OX40-OX40L Inhibition for the Treatment of Atopic Dermatitis-Focus on Rocatinlimab and Amlitelimab.
    Lé AM; Torres T
    Pharmaceutics; 2022 Dec; 14(12):. PubMed ID: 36559247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of amlitelimab, a fully human nondepleting, noncytotoxic anti-OX40 ligand monoclonal antibody, in atopic dermatitis: results of a phase IIa randomized placebo-controlled trial.
    Weidinger S; Bieber T; Cork MJ; Reich A; Wilson R; Quaratino S; Stebegg M; Brennan N; Gilbert S; O'Malley JT; Porter-Brown B
    Br J Dermatol; 2023 Oct; 189(5):531-539. PubMed ID: 37463508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study.
    Guttman-Yassky E; Simpson EL; Reich K; Kabashima K; Igawa K; Suzuki T; Mano H; Matsui T; Esfandiari E; Furue M
    Lancet; 2023 Jan; 401(10372):204-214. PubMed ID: 36509097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. OX40 in the Pathogenesis of Atopic Dermatitis-A New Therapeutic Target.
    Croft M; Esfandiari E; Chong C; Hsu H; Kabashima K; Kricorian G; Warren RB; Wollenberg A; Guttman-Yassky E
    Am J Clin Dermatol; 2024 May; 25(3):447-461. PubMed ID: 38236520
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Summary of Research: An Anti-OX40 Antibody to Treat Moderate-to-Severe Atopic Dermatitis: A Multicentre, Double-Blind, Placebo-Controlled Phase 2b Study.
    Guttman-Yassky E; Simpson EL; Reich K; Kabashima K; Igawa K; Suzuki T; Mano H; Matsui T; Esfandiari E; Furue M
    Adv Ther; 2024 Mar; 41(3):928-931. PubMed ID: 38185777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging drugs for the treatment of atopic dermatitis: a focus on phase 2 and phase 3 trials.
    Obed O; Chong AC; Su M; Ong PY
    Expert Opin Emerg Drugs; 2024 Apr; ():1-17. PubMed ID: 38662529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An OX-Tra'Ordinary Tale: The Role of OX40 and OX40L in Atopic Dermatitis.
    Sadrolashrafi K; Guo L; Kikuchi R; Hao A; Yamamoto RK; Tolson HC; Bilimoria SN; Yee DK; Armstrong AW
    Cells; 2024 Mar; 13(7):. PubMed ID: 38607026
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Role of OX40-OX40L Axis in the Pathogenesis of Atopic Dermatitis.
    Schettini N; Pacetti L; Corazza M; Borghi A
    Dermatitis; 2024 May; ():. PubMed ID: 38700255
    [No Abstract]   [Full Text] [Related]  

  • 9. The role of OX40L/OX40 axis signalling in atopic dermatitis.
    Guttman-Yassky E; Croft M; Geng B; Rynkiewicz N; Lucchesi D; Peakman M; van Krinks C; Valdecantos W; Xing H; Weidinger S
    Br J Dermatol; 2024 Jun; ():. PubMed ID: 38836560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. OX40L-OX40 Signaling in Atopic Dermatitis.
    Furue M; Furue M
    J Clin Med; 2021 Jun; 10(12):. PubMed ID: 34208041
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GBR 830, an anti-OX40, improves skin gene signatures and clinical scores in patients with atopic dermatitis.
    Guttman-Yassky E; Pavel AB; Zhou L; Estrada YD; Zhang N; Xu H; Peng X; Wen HC; Govas P; Gudi G; Ca V; Fang H; Salhi Y; Back J; Reddy V; Bissonnette R; Maari C; Grossman F; Wolff G
    J Allergy Clin Immunol; 2019 Aug; 144(2):482-493.e7. PubMed ID: 30738171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase 2b randomized trial of OX40 inhibitor telazorlimab for moderate-to-severe atopic dermatitis.
    Rewerska B; Sher LD; Alpizar S; Pauser S; Pulka G; Mozaffarian N; Salhi Y; Martinet C; Jabert W; Gudi G; Ca V; Gn S; Macoin J; Anstett V; Turrini R; Doucey MA; Blein S; Konto C; Machkova M
    J Allergy Clin Immunol Glob; 2024 Feb; 3(1):100195. PubMed ID: 38187863
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An overview of new and emerging antibody therapies for moderate-severe atopic dermatitis in adults.
    Picone V; Vallone Y; Patruno C; Napolitano M
    Expert Rev Clin Pharmacol; 2023; 16(12):1239-1248. PubMed ID: 38054328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. OX40 ligand and OX40 are increased in atopic dermatitis lesions but do not correlate with clinical severity.
    Ilves T; Harvima IT
    J Eur Acad Dermatol Venereol; 2013 Feb; 27(2):e197-205. PubMed ID: 22646697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial.
    Reich K; Teixeira HD; de Bruin-Weller M; Bieber T; Soong W; Kabashima K; Werfel T; Zeng J; Huang X; Hu X; Hendrickson BA; Ladizinski B; Chu AD; Silverberg JI
    Lancet; 2021 Jun; 397(10290):2169-2181. PubMed ID: 34023009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial.
    Thaçi D; Simpson EL; Beck LA; Bieber T; Blauvelt A; Papp K; Soong W; Worm M; Szepietowski JC; Sofen H; Kawashima M; Wu R; Weinstein SP; Graham NM; Pirozzi G; Teper A; Sutherland ER; Mastey V; Stahl N; Yancopoulos GD; Ardeleanu M
    Lancet; 2016 Jan; 387(10013):40-52. PubMed ID: 26454361
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials.
    Guttman-Yassky E; Teixeira HD; Simpson EL; Papp KA; Pangan AL; Blauvelt A; Thaçi D; Chu CY; Hong HC; Katoh N; Paller AS; Calimlim B; Gu Y; Hu X; Liu M; Yang Y; Liu J; Tenorio AR; Chu AD; Irvine AD
    Lancet; 2021 Jun; 397(10290):2151-2168. PubMed ID: 34023008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The OX40 Axis is Associated with Both Systemic and Local Involvement in Atopic Dermatitis.
    Elsner JS; Carlsson M; Stougaard JK; Nygaard U; Buchner M; Fölster-Holst R; Hvid M; Vestergaard C; Deleuran M; Deleuran B
    Acta Derm Venereol; 2020 Mar; 100(6):adv00099. PubMed ID: 32176307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
    Simpson EL; Sinclair R; Forman S; Wollenberg A; Aschoff R; Cork M; Bieber T; Thyssen JP; Yosipovitch G; Flohr C; Magnolo N; Maari C; Feeney C; Biswas P; Tatulych S; Valdez H; Rojo R
    Lancet; 2020 Jul; 396(10246):255-266. PubMed ID: 32711801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of Multiple Dupilumab Dose Regimens After Initial Successful Treatment in Patients With Atopic Dermatitis: A Randomized Clinical Trial.
    Worm M; Simpson EL; Thaçi D; Bissonnette R; Lacour JP; Beissert S; Kawashima M; Ferrándiz C; Smith CH; Beck LA; Chan KC; Chen Z; Akinlade B; Hultsch T; Staudinger H; Gadkari A; Eckert L; Davis JD; Rajadhyaksha M; Graham NMH; Pirozzi G; Stahl N; Yancopoulos GD; Ardeleanu M
    JAMA Dermatol; 2020 Feb; 156(2):131-143. PubMed ID: 31876900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.